Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03549260 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Efficacy and Safety of LIB003 in Patients on Lipid-Lowering Therapy Needing Additional LDL-C Reduction
A Phase 2 study of LDL Cholesterol, sponsored by LIB Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
- 5
- Study locations
NCT03549260: Completed Phase 2 study of LDL Cholesterol, sponsored by LIB Therapeutics.
NCT03549260 is a Phase 2 study of LDL Cholesterol that has completed, run by LIB Therapeutics. The registered enrollment target is 81 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (39% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03549260, a Phase 2 study of LDL Cholesterol, has completed, sponsored by LIB Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
- 5
- Study locations
Study Summary
Study to assess the LDL-C lowering efficacy of different doses of LIB003 administered every 4 weeks in subjects on stable statin and/or ezetimibe therapy
Primary Outcome
Change in serum LDL-C from baseline after 12 weeks
Conditions Studied
Interventions
- BIOLOGICAL LIB003
Study Locations (5)
Ohio
- Sterling Research Group - Cincinnati
- The Lindner Research Center - Cincinnati
- Metabolic & Atherosclerosis Research Center (MARC) - Cincinnati
Indiana
- Midwest Institute For Clinical Research - Indianapolis
Kentucky
- Louisville Metabolic and Atherosclerosis Research Center - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2018-05-22 |
| Est. Completion | 2018-11-30 |
| Phase | Phase 2 |
What the finished NCT03549260 record still lists
NCT03549260 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (39% lower).
The record links to 1 condition, with LDL Cholesterol appearing as the primary indexed condition, and to 1 intervention - of which LIB003 is the first listed.
NCT03549260 lists 5 locations in 3 states (Ohio, Indiana, Kentucky).
Frequently Asked Questions
What is clinical trial NCT03549260 about?
NCT03549260 is a clinical study titled "Study to Evaluate Efficacy and Safety of LIB003 in Patients on Lipid-Lowering Therapy Needing Additional LDL-C Reduction". Study to assess the LDL-C lowering efficacy of different doses of LIB003 administered every 4 weeks in subjects on stable statin and/or ezetimibe therapy
What is the current status of trial NCT03549260?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2018-05-22. Estimated completion is 2018-11-30.
What conditions does trial NCT03549260 study?
This clinical trial studies the following conditions: LDL Cholesterol.
What interventions are being tested in trial NCT03549260?
The interventions under investigation include: LIB003 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03549260?
This trial is sponsored by LIB Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03549260 being conducted?
This trial has 5 study locations across Indiana, Kentucky, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03549260's enrollment target sits among peer trials
81 834th of 2000 higher than 1,159 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI